Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2001-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this trial is to establish the dose response relationship on glycaemic control of five dose levels of NNC90-1170.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Glimepiride; Liraglutide

Criteria

Inclusion Criteria:

• Subjects with type 2 diabetes

• Duration of diabetes at least 3 months

• Both diet treated and patients in therapy with OHA (oral hypoglycemic agents)

• Body Mass Index maximum 40 kg/m^2

• HbA1c based on analysis from central laboratory: Between 7.5-10.0%, both inclusive, for diet treated, or maximum 9.0% for OHA treated

Exclusion Criteria:

• Liver or renal disease

• Cardiac problems

• Uncontrolled treated/untreated hypertension

• Proliferative retinopathy

• Recurrent severe hypoglycaemia as judged by the Investigator

• Known or suspected allergy to trial product or related products

• Use of any drug (except for OHAs) which in the Investigator's opinion could interfere with the blood glucose level